Blau Farmaceutica SA BLAU3
BMFBOVESPA · Brazil · Health Technology
BRL 10.70-0.01 (-0.09%)
Market open· · BRL · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · BRL · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Blau Farmaceutica SA (BSP:BLAU3) reports 10% revenue growth and 25% recurring EBITDA margin, with free cash flow of $70 million in the first half of 2026.
Blau Farmaceutica SA (BSP:BLAU3) reports a 39% increase in net income and significant investments in biotechnology, despite challenges in production capacity and federal bidding delays.
Blau Farmaceutica SA reports an impressive 52% increase in net income, while addressing production bottlenecks and strategic investments for future growth.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.